Back To Search Instructions
Protocols
21 protocol(s) meet the specified criteria
Age Group: A
Disease Site: Kidney
Protocol No.TitleStatus
14083An Open-Label, Dose-Escalation, Phase I/II Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of the MEK Inhibitor Trametinib in Children and Adolescent Subjects with Cancer or Plexiform Neurofibromas and Trametinib in Combination with Dabrafenib in Children and Adolescents with Cancers Harboring V600 MutationsOpen
15084Discovering Therapeutic Targets Using Circulating Tumor DNA in Pediatric Patients with Solid and CNS Malignancies: A Pilot Study Open
166510Biomarkers of Pulmonary and Renal FibrosisOpen
16702A Phase 1/1b, Open-Label, Multicenter, Repeat-Dose, Dose-Selection Study of CPI-444 as Single Agent and in Combination with Atezolizumab in Patients with Selected Incurable CancersOpen
16954Phase 1/2 Study of CORT125134 in Combination with Nab-paclitaxel in Patients with Solid TumorsOpen
175211A Phase 1b dose-escalation and dose-expansion study of enfortumab vedotin (ASG-22CE) in combination with immune checkpoint inhibitor (CPI) therapy for treatment of patients with locally advanced or metastatic urothelial cancerOpen
17527CTT1057, a Small Molecular Inhibitor of Prostate Specific Membrane Antigen (PSMA), as a Novel Imaging Agent of Neovascularization in Renal Cell Carcinoma: A Pilot StudyOpen
17955Phase 1 / 2 Multicenter Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of APL-101 in Subjects with Non-Small Cell Lung Cancer with c-Met EXON 14 skip mutations and c-Met Dysregulation Advance Solid TumorsOpen
17959A Phase 1 Study of MK-3475 (Pembrolizumab) in Combination with Recombinant Interleukin-12 in Patients with Solid TumorsOpen
18525Hyperpolarized 13C pyruvate metabolic MRI to predict renal tumor aggressivenessOpen
189510Phase II Trial of AZD6738 Alone and in Combination with Olaparib in Patients with Selected Solid Tumor MalignanciesOpen
189511A Phase 1 Multiple Dose Study to Evaluate the Safety and Tolerability of XmAb®20717 in Subjects with Selected Advanced Solid Tumors (DUET-2)Open
18952A Phase 2 Study of AZD1775 in SETD2-Deficient Advanced Solid Tumor MalignanciesOpen
APEC1621ANCI-COG PEDIATRIC MATCH (MOLECULAR ANALYSIS FOR THERAPY CHOICE)-PHASE 2 SUBPROTOCOL OF LOXO-101 (LAROTRECTINIB) IN PATIENTS WITH TUMORS HARBORING ACTIONABLE NTRK FUSIONSOpen
APEC1621BAPEC1621B, NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 subprotocol of JNJ-42756493 (erdafitinib) in patients with tumors harboring FGFR1/2/3/4 alterationsOpen
APEC1621DAPEC1621D: NCI-COG PEDIATRIC MATCH (MOLECULAR ANALYSIS FOR THERAPY CHOICE)- PHASE 2 SUBPROTOCOL OF LY3023414 IN PATIENTS WITH SOLID TUMORSOpen
APEC1621GNCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 subprotocol of Vemurafenib in patients with tumors harboring actionable BRAF V600 mutationsOpen
APEC1621HNCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 subprotocol of olaparib in patients with tumors harboring defects in DNA damage repair genesOpen
APEC1621INCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of Palbociclib in Patients With Tumors Harboring Activating Alterations in Cell Cycle GenesOpen
APEC1621JNCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of BVD-523FB (Ulixertinib) in Patients With Tumors Harboring Activating MAPK Pathway MutationsOpen
APEC1621SCNCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening ProtocolOpen